EPHA2 and neoplasm: The small-molecule inhibitor GLPG1790 blocks EphA2 phosphorylation at Tyr588 and Ser897, modulates differentiation markers, and reduces tumor growth, showing synergy with standard therapies (Gravina et al., 2019).